MASI Quote, Financials, Valuation and Earnings

Integra LifeSciences Holdings Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of -1.34%. Masimo Corp.'s return on equity of -19.18% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 34.12%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 23.31%. Given that Masimo Corp. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Masimo Corp. is more attractive than Integra LifeSciences Holdings Corp..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Masimo Corp.'s net income of $53.7M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.33x versus 0.59x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 12.4%. Masimo Corp.'s return on equity of -19.18% beat Insulet Corp.'s return on equity of 18.92%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 34.12%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 29.55%. Given that Masimo Corp. has higher upside potential than Insulet Corp., analysts believe Masimo Corp. is more attractive than Insulet Corp..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Masimo Corp.'s net income of $53.7M is lower than Insulet Corp.'s net income of $87.6M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Insulet Corp.'s PE ratio is 84.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.33x versus 8.37x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

UFP Technologies, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 10.6%. Masimo Corp.'s return on equity of -19.18% beat UFP Technologies, Inc.'s return on equity of 18.42%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 34.12%. On the other hand UFP Technologies, Inc. has an analysts' consensus of $329.50 which suggests that it could grow by 43.47%. Given that UFP Technologies, Inc. has higher upside potential than Masimo Corp., analysts believe UFP Technologies, Inc. is more attractive than Masimo Corp..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison UFP Technologies, Inc. has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.324%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. UFP Technologies, Inc. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are larger than UFP Technologies, Inc. quarterly revenues of $154.6M. Masimo Corp.'s net income of $53.7M is higher than UFP Technologies, Inc.'s net income of $16.4M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while UFP Technologies, Inc.'s PE ratio is 26.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.33x versus 2.99x for UFP Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 17.41%. Masimo Corp.'s return on equity of -19.18% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 34.12%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 25.77%. Given that Masimo Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Masimo Corp. is more attractive than West Pharmaceutical Services, Inc..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Masimo Corp. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Masimo Corp.'s net income of $53.7M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while West Pharmaceutical Services, Inc.'s PE ratio is 40.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.33x versus 6.64x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.